Adapted from Myers J, Braunstein SL, Xia Q, et al. Redefining prevention and care: a status-neutral approach to HIV. Open Forum Infect Dis. June 2; 5(6):ofy097; 2018. doi: 10.1093/ofid/ofy097
ART=antiretroviral therapy; PrEP=Pre-Exposure Prophylaxis; TasP=Treatment as Prevention; PEP=Post-Exposure Prophylaxis.
References:
- U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Initiation of antiretroviral therapy. Updated December 18, 2019. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/initiation-antiretroviral-therapy
- U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Baseline evaluation. Updated May 1, 2014. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/baseline-evaluation
- U.S. Department of Health and Human Services. Clinical guidelines. Accessed October 13, 2021. https://clinicalinfo.hiv.gov/en/guidelines
- World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Published July 16, 2021. Accessed October 13, 2021. https://www.who.int/publications/i/item/9789240031593
- Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA. 2020;324(16):1651-1669.
Connect With Our Medical Experts
Find My ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1‑888‑226‑8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.